Exact Mass: 404.1

Exact Mass Matches: 404.1

Found 44 metabolites which its exact mass value is equals to given mass value 404.1, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Mollicellin D

13-chloro-5,14-dihydroxy-15-(hydroxymethyl)-7,12-dimethyl-6-(3-methylbut-2-en-1-yl)-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaen-10-one

C21H21ClO6 (404.1027)

Mollicellin D is produced by Chaetomium species and mycotoxin. Production by Chaetomium subspecies and mycotoxin.

Glyceryl lactopalmitate

3-[6-(2,6-dimethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl]-5-phenyl-1H-pyrazole

C20H16N6O2S (404.1055)

Glyceryl lactopalmitate is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")

Zopiclone N-oxide

6-(5-Chloro-2-pyridyl)-7-((4-oxo-4-methyl-1-piperazinyl)carbonyloxy)-6,7-dihydro(5H)pyrrolo(3,4-b)pyrazin-5-one

C17H17ClN6O4 (404.1)

Zopiclone N-oxide is a primary, active metabolite of zopiclone. Zopiclone (brand names Imovane, Zimovane, and Dopareel) is a nonbenzodiazepine hypnotic agent used in the treatment of insomnia. Zopiclone is molecularly distinct from benzodiazepine drugs and belongs to the class of drugs known as cyclopyrrolones. However, zopiclone increases the normal transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via modulating benzodiazepine receptors in the same way that benzodiazepine drugs do (Wikipedia).

Ipragliflozin

2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H21FO5S (404.1094)

DSSTox_CID_27274

C17H19F3N2O4S (404.1018)

ZINC1039421

C19H15F3N4O3 (404.1096)

Tosufloxacin

tosufloxacin tosilate

C19H15F3N4O3 (404.1096)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic

CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3461; ORIGINAL_PRECURSOR_SCAN_NO 3459 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3459; ORIGINAL_PRECURSOR_SCAN_NO 3456 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3469; ORIGINAL_PRECURSOR_SCAN_NO 3467 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3454; ORIGINAL_PRECURSOR_SCAN_NO 3452 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3530; ORIGINAL_PRECURSOR_SCAN_NO 3529 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3463; ORIGINAL_PRECURSOR_SCAN_NO 3461 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7200; ORIGINAL_PRECURSOR_SCAN_NO 7197 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7214; ORIGINAL_PRECURSOR_SCAN_NO 7212 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7239; ORIGINAL_PRECURSOR_SCAN_NO 7236 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7248; ORIGINAL_PRECURSOR_SCAN_NO 7245 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7237; ORIGINAL_PRECURSOR_SCAN_NO 7235 CONFIDENCE standard compound; INTERNAL_ID 265; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7250; ORIGINAL_PRECURSOR_SCAN_NO 7248

Met-Phe-OH

(S)-2-(3-(2-(methylthio)ethoxy)-4-nitrobenzamido)-3-phenylpropanoic acid

C19H20N2O6S (404.1042)

Phe-Met-OH

(S)-2-(3-(benzyloxy)-4-nitrobenzamido)-5-(methylthio)pentanoic acid

C19H20N2O6S (404.1042)

Glyceryl lactopalmitate

5-[6-(2,6-dimethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl]-3-phenyl-1H-pyrazole

C20H16N6O2S (404.1055)

Mollicellin D

13-chloro-5,14-dihydroxy-15-(hydroxymethyl)-7,12-dimethyl-6-(3-methylbut-2-en-1-yl)-2,9-dioxatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one

C21H21ClO6 (404.1027)

TC-S 7006

C21H14ClFN6 (404.0952)

2-naphthyl 4-phenylazophenyl phosphate*

C22H17N2O4P (404.0926)

2,2-[1,4-phenylenebis (carbonylimino)] bis-Benzoic acid

C22H16N2O6 (404.1008)

1-Naphthyl 4-phenylazophenyl phosphate

C22H17N2O4P (404.0926)

3-(METHOXYCARBONYL)-5-(((4-NITROBENZYL)OXY)CARBONYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE-2-CARBOXYLIC ACID

C17H16N4O8 (404.0968)

NS 3763

C22H16N2O6 (404.1008)

1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid

C19H15F3N4O3 (404.1096)

Ipragliflozin

C21H21FO5S (404.1094)

A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor

2-Chloro-5-(tributylstannyl)pyrimidine

C16H29ClN2Sn (404.1041)

9-fluorenylmethyl n-(5-aminopentyl)carbamate hydrobromide

C20H25BrN2O2 (404.1099)

quinine hydrobromide

C20H25BrN2O2 (404.1099)

98Z99JE779

C19H20N2O6S (404.1042)

Ethydiaminedhephen acetic sodium salt

C18H18N2Na2O6 (404.096)

5-(p-Nitrophenyl)thioadenosine

C16H16N6O5S (404.0903)

Acetic acid, (4-((2R)-2-(((2S)-2-hydroxy-2-(2-(trifluoromethyl)-4-thiazolyl)ethyl)amino)propyl)phenoxy)-

C17H19F3N2O4S (404.1018)

N-(4-acetylphenyl)-2-[[3-(2-pyridinyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]thio]acetamide

C20H16N6O2S (404.1055)

Eszopiclone N-Oxide

C17H17ClN6O4 (404.1)

N-[2-(4-Carboxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(2-trifluoromethyl-thiazol-4-yl)ethanamine

C17H19F3N2O4S (404.1018)

(S)-tosufloxacin

C19H15F3N4O3 (404.1096)

2-(2-Fluorophenyl)-4-(4-fluorophenyl)sulfonyl-5-(1-piperidinyl)oxazole

C20H18F2N2O3S (404.1006)

N(2),N(2),N(7)-trimethylguanosine 5-phosphate(1-)

C13H19N5O8P- (404.0971)

2-[4-(4-Chlorophenyl)sulfonyl-1-piperazinyl]-1-ethylbenzimidazole

C19H21ClN4O2S (404.1074)

N-[(4-nitrophenyl)methylene]-2-(10H-phenothiazin-10-yl)acetohydrazide

C21H16N4O3S (404.0943)

N-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-(4-methylpiperidin-1-yl)acetamide

C21H22Cl2N2O2 (404.1058)

(R)-tosufloxacin

C19H15F3N4O3 (404.1096)

Cabotegravir anion

C19H16F2N3O5- (404.1058)

(S)-N-Oxidezopiclone

C17H17ClN6O4 (404.1)

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] butanoate

C13H25O12P (404.1084)

LPI 4:0

C13H25O12P (404.1084)

Leramistat

C20H21ClN2O3S (404.0961)

Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease[1][2][3].